Blueprint Medicines Corporation Stock News

Blueprint Medicines (NASDAQ:BPMC) had its price objective hoisted by Deutsche Bank from $85.00 to $95.00 in a research report report published on Wednesday, The Fly reports. The brokerage currently ha

Blueprint Medicines Corp (NASDAQ:BPMC) – Wedbush boosted their Q2 2020 earnings per share estimates for Blueprint Medicines in a research report issued on Tuesday, July 14th. Wedbush analyst D. Nier

Blueprint Medicines Corp (NASDAQ:BPMC)’s stock price gapped up prior to trading on Tuesday after Robert W. Baird raised their price target on the stock from $90.00 to $100.00. The stock had previous

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.

Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.

Blueprint Medicines stock popped Tuesday on a $775 million deal with pharma giant Roche to sell a cancer treatment, pralsetinib. The drug targets abnormalities in the RET gene.

Stocks are set to open higher Tuesday as Wall Street evaluates earnings from major U.S. banks.

Shares of Blueprint Medicines Corp. gained 8.3% in premarket trading on Tuesday, the day after the company announced a deal with Roche Holding AG to develop and commercialize pralsetinib, an investi

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) * Altimmune Inc (NASDAQ: ALT) (announced positive pre

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines, it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments. The Sw

Roche Holding AG said Tuesday that it will invest and codevelop a lung-cancer drug with U.S. company Blueprint Medicines Corp. The two companies will develop...

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has entered into a g

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes